2019 update to: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

The American Diabetes Association and the European Association for the Study of Diabetes have briefly updated their 2018 recommendations on management of hyperglycaemia, based on important research findings from large cardiovascular outcomes trials published in 2019. Important changes include: (1) t...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	Diabetologia Ročník 63; číslo 2; s. 221 - 228
Hlavní autoři:	Buse, John B., Wexler, Deborah J., Tsapas, Apostolos, Rossing, Peter, Mingrone, Geltrude, Mathieu, Chantal, D’Alessio, David A., Davies, Melanie J.
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	Berlin/Heidelberg Springer Berlin Heidelberg 01.02.2020 Springer Nature B.V
Témata:	Agonists Cardiovascular diseases Cardiovascular Diseases - metabolism Clinical trials Congestive heart failure Consensus Report Update Creatinine Death Diabetes Diabetes mellitus (non-insulin dependent) Diabetes Mellitus, Type 2 - drug therapy Diabetes Mellitus, Type 2 - metabolism Epidermal growth factor receptors Europe GLP-1 receptor agonists Glucagon Glucagon-Like Peptide-1 Receptor - agonists Glycated Hemoglobin A - metabolism Health risk assessment Heart failure Human Physiology Humans Hyperglycemia Hypoglycemia Hypoglycemic Agents - therapeutic use Internal Medicine Kidney diseases Medicine Medicine & Public Health Metabolic Diseases Patient-centered care Societies, Medical Sodium-glucose cotransporter Sodium-Glucose Transporter 2 Inhibitors - therapeutic use United States United States Europe Heart failure Patient-centred care Glucose-lowering therapy Hypoglycaemia Cardiovascular disease Chronic kidney disease Type 2 diabetes mellitus Guidelines
ISSN:	0012-186X, 1432-0428, 1432-0428
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Popis
Shrnutí:	The American Diabetes Association and the European Association for the Study of Diabetes have briefly updated their 2018 recommendations on management of hyperglycaemia, based on important research findings from large cardiovascular outcomes trials published in 2019. Important changes include: (1) the decision to treat high-risk individuals with a glucagon-like-peptide 1 (GLP-1) receptor agonist or sodium–glucose cotransporter 2 (SGLT2) inhibitor to reduce major adverse cardiovascular events (MACE), hospitalisation for heart failure (hHF), cardiovascular death or chronic kidney disease (CKD) progression should be considered independently of baseline HbA 1c or individualised HbA 1c target; (2) GLP-1 receptor agonists can also be considered in patients with type 2 diabetes without established cardiovascular disease (CVD) but with the presence of specific indicators of high risk; and (3) SGLT2 inhibitors are recommended in patients with type 2 diabetes and heart failure, particularly those with heart failure with reduced ejection fraction, to reduce hHF, MACE and CVD death, as well as in patients with type 2 diabetes with CKD (eGFR 30 to ≤60 ml min −1 [1.73 m] −2 or urinary albumin-to-creatinine ratio >30 mg/g, particularly >300 mg/g) to prevent the progression of CKD, hHF, MACE and cardiovascular death.
Bibliografie:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23
ISSN:	0012-186X 1432-0428 1432-0428
DOI:	10.1007/s00125-019-05039-w